Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1995 Oct;69(10):6077–6089. doi: 10.1128/jvi.69.10.6077-6089.1995

Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.

M D Lairmore 1, A M DiGeorge 1, S F Conrad 1, A V Trevino 1, R B Lal 1, P T Kaumaya 1
PMCID: PMC189504  PMID: 7545241

Abstract

Conventional strategies of viral peptide immunizations often elicit low-affinity antibody responses and have limited ability to elicit immune responses in outbred animals of diverse major histocompatibility (MHC) haplotypes. This genetically restricted T-cell-stimulatory activity of peptides is a serious obstacle to vaccine design. However, the use of promiscuous T-cell epitopes may circumvent this problem. Promiscuous T-cell epitopes from tetanus toxin (amino acids [aa] 580 to 599) and the measles virus F protein (aa 288 to 302) that bind to several isotypic and allotypic forms of human MHC class II molecules have been identified and have been used in highly immunogenic constructs to overcome haplotype-restricted immune responses. Chimeric and beta-template peptide constructs incorporating known human T-lymphotropic virus type 1 (HTLV-1) B- and T-cell epitopes from the surface envelope protein gp46 (SP2 [aa 86 to 107] and SP4a [aa 190 to 209]) and promiscuous T-cell peptides were synthesized, and their immunogenicities were evaluated in both rabbits and mouse strains of divergent haplotypes (C3H/HeJ [H-2k], C57BL/6 [H-2b], and BALB/c [H-2d]). In addition, peptide preparations were structurally characterized by analytical high-performance liquid chromatography, mass spectrometry, and circular dichroism. In contrast to their linear forms, the chimeric constructs of both the SP2 and SP4a epitopes displayed alpha-helical secondary structures. Immunogenicity of the peptide constructs was evaluated by direct and competitive enzyme-linked immunosorbant assay (ELISA), as well as by radioimmunoprecipitation, syncytium inhibition, and antigen-induced lymphocyte proliferation assays. Immunization with the SP4a peptide without conjugation to a carrier protein produced antibodies specific for SP4a in two mouse strains (C3H/HeJ and C57BL/6). However, BALB/c mice failed to respond to the peptide, indicating that the T-cell epitope of the SP4a sequence is MHC restricted. In contrast, the chimeric constructs MVF-SP2 and SP4a-measles virus F protein were highly immunogenic, producing elevated ELISA titers after only two immunizations. Elicited antibodies recognized native forms of gp46 in ELISAs and radioimmunoprecipitation assays, as well as inhibited HTLV-1-mediated syncytium formation. In addition, chimeric constructs were effective at induction of lymphocyte proliferation to the T-cell epitope, SP4a, in each strain of immunized mice. Our data demonstrate that the antibody response to retroviral peptides is enhanced by promiscuous peptide constructs, in part because of the ability of such constructs to promote appropriate secondary structural forms of viral epitopes. In addition, these constructs promote virus-specific helper T-cell responses, thereby overcoming genetically restricted immune responses to the synthetic peptides.

Full Text

The Full Text of this article is available as a PDF (669.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amit A. G., Mariuzza R. A., Phillips S. E., Poljak R. J. Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution. Science. 1986 Aug 15;233(4765):747–753. doi: 10.1126/science.2426778. [DOI] [PubMed] [Google Scholar]
  2. Baba E., Nakamura M., Ohkuma K., Kira J., Tanaka Y., Nakano S., Niho Y. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies. J Immunol. 1995 Jan 1;154(1):399–412. [PubMed] [Google Scholar]
  3. Baba E., Nakamura M., Tanaka Y., Kuroki M., Itoyama Y., Nakano S., Niho Y. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine. J Immunol. 1993 Jul 15;151(2):1013–1024. [PubMed] [Google Scholar]
  4. Babbitt B. P., Allen P. M., Matsueda G., Haber E., Unanue E. R. Binding of immunogenic peptides to Ia histocompatibility molecules. 1985 Sep 26-Oct 2Nature. 317(6035):359–361. doi: 10.1038/317359a0. [DOI] [PubMed] [Google Scholar]
  5. Berzofsky J. A. Antigenic peptide interaction with MHC molecules: implications for the design of artificial vaccines. Semin Immunol. 1991 Jul;3(4):203–216. [PubMed] [Google Scholar]
  6. Berzofsky J. A. Mechanisms of T cell recognition with application to vaccine design. Mol Immunol. 1991 Mar;28(3):217–223. doi: 10.1016/0161-5890(91)90064-q. [DOI] [PubMed] [Google Scholar]
  7. Berzofsky J. A., Pendleton C. D., Clerici M., Ahlers J., Lucey D. R., Putney S. D., Shearer G. M. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J Clin Invest. 1991 Sep;88(3):876–884. doi: 10.1172/JCI115389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bjorkman P. J., Saper M. A., Samraoui B., Bennett W. S., Strominger J. L., Wiley D. C. Structure of the human class I histocompatibility antigen, HLA-A2. Nature. 1987 Oct 8;329(6139):506–512. doi: 10.1038/329506a0. [DOI] [PubMed] [Google Scholar]
  9. Borras-Cuesta F., Petit-Camurdan A., Fedon Y. Engineering of immunogenic peptides by co-linear synthesis of determinants recognized by B and T cells. Eur J Immunol. 1987 Aug;17(8):1213–1215. doi: 10.1002/eji.1830170820. [DOI] [PubMed] [Google Scholar]
  10. Borras-Cuesta F., Petit-Camurdan A., Fedon Y. Engineering of immunogenic peptides by co-linear synthesis of determinants recognized by B and T cells. Eur J Immunol. 1987 Aug;17(8):1213–1215. doi: 10.1002/eji.1830170820. [DOI] [PubMed] [Google Scholar]
  11. Chen Y. H., Yang J. T., Chau K. H. Determination of the helix and beta form of proteins in aqueous solution by circular dichroism. Biochemistry. 1974 Jul 30;13(16):3350–3359. doi: 10.1021/bi00713a027. [DOI] [PubMed] [Google Scholar]
  12. Chen Y. M., Lee T. H., Samuel K. P., Okayama A., Tachibana N., Miyoshi I., Papas T. S., Essex M. Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people. J Virol. 1989 Nov;63(11):4952–4957. doi: 10.1128/jvi.63.11.4952-4957.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Chou P. Y., Fasman G. D. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol. 1978;47:45–148. doi: 10.1002/9780470122921.ch2. [DOI] [PubMed] [Google Scholar]
  14. Clarke B. E., Newton S. E., Carroll A. R., Francis M. J., Appleyard G., Syred A. D., Highfield P. E., Rowlands D. J., Brown F. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. 1987 Nov 26-Dec 2Nature. 330(6146):381–384. doi: 10.1038/330381a0. [DOI] [PubMed] [Google Scholar]
  15. Corradin G., Etlinger H. M., Chiller J. M. Lymphocyte specificity to protein antigens. I. Characterization of the antigen-induced in vitro T cell-dependent proliferative response with lymph node cells from primed mice. J Immunol. 1977 Sep;119(3):1048–1053. [PubMed] [Google Scholar]
  16. Francis M. J., Hastings G. Z., Syred A. D., McGinn B., Brown F., Rowlands D. J. Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature. 1987 Nov 12;330(6144):168–170. doi: 10.1038/330168a0. [DOI] [PubMed] [Google Scholar]
  17. Gessain A., Barin F., Vernant J. C., Gout O., Maurs L., Calender A., de Thé G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985 Aug 24;2(8452):407–410. doi: 10.1016/s0140-6736(85)92734-5. [DOI] [PubMed] [Google Scholar]
  18. Hartley T. M., Khabbaz R. F., Cannon R. O., Kaplan J. E., Lairmore M. D. Characterization of antibody reactivity to human T-cell lymphotropic virus types I and II using immunoblot and radioimmunoprecipitation assays. J Clin Microbiol. 1990 Apr;28(4):646–650. doi: 10.1128/jcm.28.4.646-650.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ho P. C., Mutch D. A., Winkel K. D., Saul A. J., Jones G. L., Doran T. J., Rzepczyk C. M. Identification of two promiscuous T cell epitopes from tetanus toxin. Eur J Immunol. 1990 Mar;20(3):477–483. doi: 10.1002/eji.1830200304. [DOI] [PubMed] [Google Scholar]
  20. Hosmalin A., Nara P. L., Zweig M., Lerche N. W., Cease K. B., Gard E. A., Markham P. D., Putney S. D., Daniel M. D., Desrosiers R. C. Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primates. J Immunol. 1991 Mar 1;146(5):1667–1673. [PubMed] [Google Scholar]
  21. Höllsberg P., Hafler D. A. Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N Engl J Med. 1993 Apr 22;328(16):1173–1182. doi: 10.1056/NEJM199304223281608. [DOI] [PubMed] [Google Scholar]
  22. Jacobson S., Reuben J. S., Streilein R. D., Palker T. J. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1. J Immunol. 1991 Feb 15;146(4):1155–1162. [PubMed] [Google Scholar]
  23. Kaumaya P. T., Berndt K. D., Heidorn D. B., Trewhella J., Kezdy F. J., Goldberg E. Synthesis and biophysical characterization of engineered topographic immunogenic determinants with alpha alpha topology. Biochemistry. 1990 Jan 9;29(1):13–23. doi: 10.1021/bi00453a002. [DOI] [PubMed] [Google Scholar]
  24. Kaumaya P. T., Kobs-Conrad S., Seo Y. H., Lee H., VanBuskirk A. M., Feng N., Sheridan J. F., Stevens V. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. J Mol Recognit. 1993 Jun;6(2):81–94. doi: 10.1002/jmr.300060206. [DOI] [PubMed] [Google Scholar]
  25. Kaumaya P. T., VanBuskirk A. M., Goldberg E., Pierce S. K. Design and immunological properties of topographic immunogenic determinants of a protein antigen (LDH-C4) as vaccines. J Biol Chem. 1992 Mar 25;267(9):6338–6346. [PubMed] [Google Scholar]
  26. Kurata A., Palker T. J., Streilein R. D., Scearce R. M., Haynes B. F., Berzofsky J. A. Immunodominant sites of human T cell lymphotropic virus type 1 envelope protein for murine helper T cells. J Immunol. 1989 Sep 15;143(6):2024–2030. [PubMed] [Google Scholar]
  27. Lairmore M. D., Rudolph D. L., Roberts B. D., Dezzutti C. S., Lal R. B. Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46. Cancer Lett. 1992 Sep 14;66(1):11–20. doi: 10.1016/0304-3835(92)90274-y. [DOI] [PubMed] [Google Scholar]
  28. Lal R. B., Giam C. Z., Coligan J. E., Rudolph D. L. Differential immune responsiveness to the immunodominant epitopes of regulatory proteins (tax and rex) in human T cell lymphotropic virus type I-associated myelopathy. J Infect Dis. 1994 Mar;169(3):496–503. doi: 10.1093/infdis/169.3.496. [DOI] [PubMed] [Google Scholar]
  29. Lal R. B., Rudolph D. L., Griffis K. P., Kitamura K., Honda M., Coligan J. E., Folks T. M. Characterization of immunodominant epitopes of gag and pol gene-encoded proteins of human T-cell lymphotropic virus type I. J Virol. 1991 Apr;65(4):1870–1876. doi: 10.1128/jvi.65.4.1870-1876.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Lal R. B., Rudolph D. L., Lairmore M. D., Khabbaz R. F., Garfield M., Coligan J. E., Folks T. M. Serologic discrimination of human T cell lymphotropic virus infection by using a synthetic peptide-based enzyme immunoassay. J Infect Dis. 1991 Jan;163(1):41–46. doi: 10.1093/infdis/163.1.41. [DOI] [PubMed] [Google Scholar]
  31. Lee A. C., Powell J. E., Tregear G. W., Niall H. D., Stevens V. C. A method for preparing beta-hCG COOH peptide-carrier conjugates of predictable composition. Mol Immunol. 1980 Jun;17(6):749–756. doi: 10.1016/0161-5890(80)90145-5. [DOI] [PubMed] [Google Scholar]
  32. Lipka J. J., Bui K., Reyes G. R., Moeckli R., Wiktor S. Z., Blattner W. A., Murphy E. L., Shaw G. M., Hanson C. V., Sninsky J. J. Determination of a unique and immunodominant epitope of human T cell lymphotropic virus type I. J Infect Dis. 1990 Aug;162(2):353–357. doi: 10.1093/infdis/162.2.353. [DOI] [PubMed] [Google Scholar]
  33. Milich D. R., McLachlan A., Thornton G. B., Hughes J. L. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature. 1987 Oct 8;329(6139):547–549. doi: 10.1038/329547a0. [DOI] [PubMed] [Google Scholar]
  34. Monaco J. J. A molecular model of MHC class-I-restricted antigen processing. Immunol Today. 1992 May;13(5):173–179. doi: 10.1016/0167-5699(92)90122-N. [DOI] [PubMed] [Google Scholar]
  35. Nagy K., Clapham P., Cheingsong-Popov R., Weiss R. A. Human T-cell leukemia virus type I: induction of syncytia and inhibition by patients' sera. Int J Cancer. 1983 Sep 15;32(3):321–328. doi: 10.1002/ijc.2910320310. [DOI] [PubMed] [Google Scholar]
  36. Osame M., Usuku K., Izumo S., Ijichi N., Amitani H., Igata A., Matsumoto M., Tara M. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986 May 3;1(8488):1031–1032. doi: 10.1016/s0140-6736(86)91298-5. [DOI] [PubMed] [Google Scholar]
  37. Padlan E. A., Silverton E. W., Sheriff S., Cohen G. H., Smith-Gill S. J., Davies D. R. Structure of an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5938–5942. doi: 10.1073/pnas.86.15.5938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Palker T. J., Matthews T. J., Langlois A., Tanner M. E., Martin M. E., Scearce R. M., Kim J. E., Berzofsky J. A., Bolognesi D. P., Haynes B. F. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J Immunol. 1989 May 15;142(10):3612–3619. [PubMed] [Google Scholar]
  39. Palker T. J., Riggs E. R., Spragion D. E., Muir A. J., Scearce R. M., Randall R. R., McAdams M. W., McKnight A., Clapham P. R., Weiss R. A. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins. J Virol. 1992 Oct;66(10):5879–5889. doi: 10.1128/jvi.66.10.5879-5889.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Palker T. J., Tanner M. E., Scearce R. M., Streilein R. D., Clark M. E., Haynes B. F. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. J Immunol. 1989 Feb 1;142(3):971–978. [PubMed] [Google Scholar]
  41. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol. 1989 Dec;19(12):2237–2242. doi: 10.1002/eji.1830191209. [DOI] [PubMed] [Google Scholar]
  42. Partidos C. D., Steward M. W. Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans. J Gen Virol. 1990 Sep;71(Pt 9):2099–2105. doi: 10.1099/0022-1317-71-9-2099. [DOI] [PubMed] [Google Scholar]
  43. Posnett D. N., McGrath H., Tam J. P. A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain. J Biol Chem. 1988 Feb 5;263(4):1719–1725. [PubMed] [Google Scholar]
  44. Roy S., Scherer M. T., Briner T. J., Smith J. A., Gefter M. L. Murine MHC polymorphism and T cell specificities. Science. 1989 May 5;244(4904):572–575. doi: 10.1126/science.2470147. [DOI] [PubMed] [Google Scholar]
  45. Sette A., Buus S., Appella E., Smith J. A., Chesnut R., Miles C., Colon S. M., Grey H. M. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A. 1989 May;86(9):3296–3300. doi: 10.1073/pnas.86.9.3296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Sette A., Buus S., Colon S., Smith J. A., Miles C., Grey H. M. Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. 1987 Jul 30-Aug 5Nature. 328(6129):395–399. doi: 10.1038/328395a0. [DOI] [PubMed] [Google Scholar]
  47. Stuhler G., Walden P. Collaboration of helper and cytotoxic T lymphocytes. Eur J Immunol. 1993 Sep;23(9):2279–2286. doi: 10.1002/eji.1830230934. [DOI] [PubMed] [Google Scholar]
  48. Tanaka Y., Tanaka R., Terada E., Koyanagi Y., Miyano-Kurosaki N., Yamamoto N., Baba E., Nakamura M., Shida H. Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization. J Virol. 1994 Oct;68(10):6323–6331. doi: 10.1128/jvi.68.10.6323-6331.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Tanaka Y., Zeng L., Shiraki H., Shida H., Tozawa H. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. J Immunol. 1991 Jul 1;147(1):354–360. [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES